This profile has not been claimed and data may not be accurate.
62nd percentile
Co-founder and CTO of PharMolix, a $15M-funded AI biotech
Credibility
Traction · 66th percentile
- PharMolix Inc. has raised $15.4M in total funding.
Relationship Matrix
Founder score
- 92%Probability of being accurate (92%)Current Co-founder and CTO of PharMolix Inc., an AI and biotech company founded in 2023.
- 85%Probability of being accurate (85%)PharMolix Inc. was co-founded with at least one other co-founder.
- 75%Probability of being accurate (75%)PharMolix Inc. has raised $15.4M in total funding.
- 72%Probability of being accurate (72%)Named inventor with a documented patent portfolio from IBM and Penn State Research Foundation.
- 70%Probability of being accurate (70%)Stack Overflow reputation of 7,147 places Mu Qiao in the 5,000–24,999 tier.
- 70%Probability of being accurate (70%)Identified Stack Overflow account with 7,147 reputation.
- 65%Probability of being accurate (65%)Identified as a researcher with a verified OpenReview profile and publications in ML/AI.
- 60%Probability of being accurate (60%)Identified Hugging Face author account @mqiao with at least one model published.
What you likely need
You're a deep-tech AI/biotech founder with serious research credentials but an early commercial stage, so the highest-leverage Festival events connect you with institutional biotech and AI investors who can anchor a Series A, and with pharma enterprise buyers who can become your first commercial contracts. You also need hiring intros to senior ML engineers and biomedical scientists who can reduce key-person risk and signal team depth. Events that sharpen your US go-to-market narrative and surface warm paths into YC's network would compound everything else.
Would you attend these IRL Festival events?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- fundraisingA Series A founder dinner with institutional biotech and AI investors (think a16z Bio, GV, and Andreessen's AI funds) to pressure-test PharMolix's 100B multimodal biomedical AI model narrative and the 2024 BEYOND Innovation Award as lead proof points
- fundraisingA YC alumni roundtable with founders from biotech and AI batches (S21–W24) who have navigated the YC application as deep-tech non-US companies, to sharpen PharMolix's application narrative and get warm intros to YC partners
- introsAn IBM Research and IBM Academy of Technology alumni dinner to surface warm introductions to pharma and biotech enterprise buyers at companies like Pfizer, Roche, and AstraZeneca for PharMolix's first commercial contracts
- hiringA happy hour for deep-tech AI founders actively hiring senior ML engineers and biomedical scientists, co-hosted with researchers spinning out of top labs (MIT CSAIL, Stanford HAI, Broad Institute) to recruit PharMolix's next 1–2 critical hires
- positioningA Hugging Face and open-source biomedical AI founder meetup with model authors who have successfully launched foundation models on Hugging Face to workshop PharMolix's model card, GitHub repo strategy, and enterprise inbound funnel
- positioningA closed-door roundtable for deep-tech founders with dual US–China presence to workshop go-to-market prioritization and investor messaging given current geopolitical dynamics, with founders who have successfully redomiciled or split operations
- tacticalAn office hours session with patent attorneys and deep-tech founders who have built defensible IP moats in multimodal AI and biomedical architectures, focused on filing continuation patents and structuring IP for Series A due diligence